Summary:
This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerbations.
Qualified Participants Must:
• Be 40 Years to 90 Years
•
Documented physician diagnosis of COPD for at least 12 months
•
History of frequent exacerbations, defined as having had two or more moderate or severe exacerbations occurring within a 12-month period in the 24 months prior to screening
•
Current or former smoker with a minimum of 10 pack-year history
Qualified Participants May Receive:
May be reimbursed for time and travel for study participation, if you qualify.